Eli Lilly and Company $LLY Shares Bought by Gerber Kawasaki Wealth & Investment Management

Gerber Kawasaki Wealth & Investment Management grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 23.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,075 shares of the company’s stock after purchasing an additional 2,280 shares during the quarter. Gerber Kawasaki Wealth & Investment Management’s holdings in Eli Lilly and Company were worth $12,986,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Summit Financial LLC lifted its stake in shares of Eli Lilly and Company by 2.5% in the fourth quarter. Summit Financial LLC now owns 15,249 shares of the company’s stock worth $16,388,000 after acquiring an additional 372 shares in the last quarter. M1 Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 2.8% in the fourth quarter. M1 Capital Management LLC now owns 548 shares of the company’s stock worth $589,000 after acquiring an additional 15 shares in the last quarter. United Capital Management of KS Inc. lifted its stake in shares of Eli Lilly and Company by 0.4% in the fourth quarter. United Capital Management of KS Inc. now owns 12,517 shares of the company’s stock worth $13,452,000 after acquiring an additional 55 shares in the last quarter. Howland Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 9.0% in the fourth quarter. Howland Capital Management LLC now owns 3,306 shares of the company’s stock worth $3,553,000 after acquiring an additional 272 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in shares of Eli Lilly and Company by 16.5% in the fourth quarter. Quadrant Capital Group LLC now owns 21,762 shares of the company’s stock worth $23,387,000 after acquiring an additional 3,088 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on LLY shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Berenberg Bank boosted their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a report on Thursday, February 19th. Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Finally, Bank of America boosted their price objective on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,227.74.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and research notes continue to turn more upbeat on Eli Lilly’s earnings outlook, with Erste Group lifting FY2026 and FY2027 EPS estimates and Goldman Sachs reiterating a buy rating on the back of an encouraging obesity-treatment pipeline. Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline
• Positive Sentiment: Eli Lilly’s strong growth story is still resonating with investors: recent coverage says the stock is in a buy zone, institutional funds are adding shares, and the company remains a leader in the GLP-1 obesity market after a big earnings beat and raised guidance. Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.
• Positive Sentiment: The company also added a new growth angle by expanding its chronic pain pipeline, including new Phase 2 trials in osteoarthritis and chronic low back pain, which could broaden Lilly’s long-term revenue base beyond obesity and diabetes. Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial
• Positive Sentiment: FDA progress for Ebglyss, including an easier once-every-eight-weeks maintenance regimen, adds another commercial catalyst and supports Lilly’s push to diversify into dermatology. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
• Neutral Sentiment: Lilly also unveiled an AI partnership with Abridge, aimed at speeding drug development, trial enrollment and research; that is strategically positive, but it is a longer-term story than a near-term earnings driver. Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth
• Negative Sentiment: A key overhang is growing concern that some employers may reduce or drop coverage for GLP-1 weight-loss drugs in 2027, which could pressure demand and reimbursement for Lilly’s obesity franchise. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases 2026-06-11

Eli Lilly and Company Stock Down 2.1%

NYSE:LLY opened at $1,137.01 on Friday. The firm has a market capitalization of $1.07 trillion, a PE ratio of 40.39, a price-to-earnings-growth ratio of 1.27 and a beta of 0.53. The stock has a 50 day moving average of $998.47 and a 200-day moving average of $1,016.72. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,182.73. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were issued a dividend of $1.73 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.